Skip to main content
Premium Trial:

Request an Annual Quote

BGI Genomics, Kangmei Pharmaceutical to Form RMB 50M Joint Venture

NEW YORK (GenomeWeb) – BGI Genomics and Kangmei Pharmaceutical are planning to form a joint venture to apply genomics to traditional Chinese medicine.

Under an agreement signed last week, the partners will invest RMB 50 million ($7.6 million) into the JV, which will be based in Shenzhen, with Kangmei providing RMB 47.5 million and BGI contributing instrumentation and technology worth RMB 2.5 million.

Kangmei, based in Puning in Guangdong Province, sells pharmaceuticals and health food products, specifically plants used in traditional Chinese medicine.

The partners originally signed a collaboration agreement at the end of October.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.